Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748695 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury
A Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01748695 is a Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01748695, a Phase 2 study of Neuropathic Pain Due to Spinal Cord Injury, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether V158866 is safe and effective for the treatment of neuropathic pain due to spinal cord injury.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG V158866
Study Locations (1)
Massachusetts
- Translational Pain Research, Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748695
The ClinicalTrials.gov registry entry for NCT01748695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathic Pain Due to Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01748695 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01748695 about?
NCT01748695 is a clinical study titled "A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury". The purpose of this study is to investigate whether V158866 is safe and effective for the treatment of neuropathic pain due to spinal cord injury.
What is the current status of trial NCT01748695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-06. Estimated completion is 2015-07.
What conditions does trial NCT01748695 study?
This clinical trial studies the following conditions: Neuropathic Pain Due to Spinal Cord Injury.
What interventions are being tested in trial NCT01748695?
The interventions under investigation include: Placebo (DRUG), V158866 (DRUG).
Who is sponsoring clinical trial NCT01748695?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01748695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.